Programing assembling/releasing multifunctional miRNA nanomedicine to treat prostate cancer.
Programing assembling/releasing multifunctional miRNA nanomedicine to treat prostate cancer.
复制标题
DOI：
10.1021/acsami.9b21707
复制
发表时间：
2020-01
影响因子：
9.5
通讯作者：
Ding Ma;Hongmei Liu;Peipei Zhao;Li Ye;Hanbing Zou;Xue Zhao;H. Dai;X. Kong;Peifeng Liu
中科院分区：
文献类型：
--
作者：
Ding Ma;Hongmei Liu;Peipei Zhao;Li Ye;Hanbing Zou;Xue Zhao;H. Dai;X. Kong;Peifeng Liu
由于激素治疗的低效率，微小RNA（miRNAs）疗法已显示出对于雄激素非依赖性前列腺癌（AIPC）的治疗具有很大的前景。然而，RNA的不稳定性和RNA治疗的无效性限制了miR-NAs在AIPC治疗中的使用。在这里，我们报告了一种pH/ATP激活的纳米复合物，用于增加miR 146 a的胞质递送，其可以有效地抑制AIPC中表皮生长因子受体（EGFR）的表达。与Lipofectamine 2000（lipo）相比，纳米复合物对DU 145细胞的侵袭、集落形成、迁移能力和生长均有相同的抑制作用。但在体内实验中，治疗5周后，与脂质体组相比，纳米复合物强烈抑制肿瘤体积的生长。这些结果证明了pH/ATP活化的纳米载体用于AIPC基因治疗的潜力。
MicroRNAs (miRNAs) therapy has shown to have great promise for the treatment of androgen-independent prostate cancer (AIPC) due to the low efficiency of hormonal therapy. However, instability of RNA and inefficiency of RNA therapy limit the use of miR-NAs in the treatment of AIPC. Here, we report a pH/ATP-activated nanocomplexes for increasing cytosolic delivery of miR146a which can effectively inhibit the expression of epidermal growth factor receptor (EGFR) in AIPC. The nanocomplexes show identi-cal suppressing effect in invasion, colony formation, migration ability and growth of DU145 cells compared with Lipofectamine 2000 (lipo). But in vivo experiment, the nanocomplexes vigorously suppress the growth of tumor volumes comparing to lipo group after 5 weeks' treatment. These results demonstrate the potential of the pH/ATP-activated nanocarriers for AIPC gene therapy.